Walter Kinney

Human papillomavirus (HPV) vaccination and cervical screening are complementary prevention measures targeting reductions in cervical precancer and cancer and other genital and oropharyngeal cancers. To maximize populationwide benefits for cervical cancer prevention, integration of vaccination and screening is critical to improve overall benefits and reduce harms and redundancies in health care costs.

Abstract OBJECTIVES: Human papillomavirus (HPV) testing for cervical screening has been shown to increase the yield of precancerous disease and reduce the incidence of cervical cancer more than cytology alone. Here we document the state-wide uptake of co-testing with HPV and cytology in women aged 30-64 years as recommended by national and international bodies.

4 DISCUSSION New Mexico is a state of approximately 2.1 million inhabitants (~35% non-Hispanic whites, 50% Hispanic Whites, 11% American Indians and small percentages of other racial groups). In 2015, approximately 600 000 women between the ages of 21 and 64 years were eligible for cervical screening.